Boston buys Celsion's Prolieve assets:
This article was originally published in Clinica
Boston Scientific is to pay $60m to purchase Celsion's Prolieve technology for treating benign prostate hyperplasia (BPH). The two companies have been partners since striking a deal in January 2003 which gave Boston exclusive US marketing and distribution rights to the FDA-approved Prolieve system, as well as an option to buy the technology. The Natick, Massachusetts firm will pay the $60m in instalments over two years. The disposal of Prolieve will transform Celsion to an oncology drug-focused company, and allow it to channel its resources on developing its lead drug, ThermoDox.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.